Agenus Inc.

415 articles about Agenus Inc.

• Agenus Reports Third Quarter 2023 Results

  11/7/2023

  Agenus Inc., a leader in discovering and developing novel immunological agents to treat various cancers, announced results for the third quarter 2023.

• Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update

  10/26/2023

  Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2023 financial results via press release before the market opens on Tuesday, November 7, 2023.

• Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

  10/22/2023

  Agenus Inc., a leader in developing novel immunological agents to treat cancers, announced first-time and updated data from its ongoing botensilimab/balstilimab clinical programs in advanced colorectal cancer, neoadjuvant CRC, pancreatic cancer, non-small cell lung cancer, melanoma, and sarcoma.

• ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes

  10/21/2023

  Agenus Inc., a leader in developing novel immunological agents to treat various cancers, announced expanded data from the company’s phase 1b study of botensilimab in combination with balstilimab in patients with advanced sarcomas.

• Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

  10/10/2023

  Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers today announced completion of the planned patient enrollment in ACTIVATE-Colorectal, a randomized Phase 2 trial in advanced colorectal cancer (CRC) evaluating the efficacy and safety of botensilimab (BOT) as monotherapy and in combination with balstilimab (BAL) or standard of care in patients with metastatic heavily pre-treated colorectal cancer.

• Agenus To Host BOT/BAL Program Update at ESMO 2023

  10/5/2023

  Agenus Inc. today announced that the Company will host a corporate event to discuss advancements in its botensilimab/balstilimab (BOT/BAL) program at the upcoming European Society for Medical Oncology (ESMO) Conference on Sunday, October 22, 2023.

• Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 01, 2023

  9/1/2023

  Agenus Inc. announced that the Compensation Committee of Agenus’ Board of Directors granted, as of September 1, 2023, inducement awards to Robin Taylor, Ph.D. in connection with his appointment as Chief Commercial Officer.

• Agenus to Participate in September 2023 Investor Conferences

  8/28/2023

  Agenus Inc., a leader in developing novel immunological agents to treat various cancers, announced that Dr. Garo Armen, Chairman and CEO, will participate in the following upcoming investor conferences.

• Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

  8/23/2023

  Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources to accelerate the development, registration, and commercialization of its flagship program botensilimab/balstilimab (BOT/BAL).

• Agenus Reports Second Quarter 2023 Results

  8/8/2023

  Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results for the second quarter 2023.

• Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023

  7/28/2023

  Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced a data update from the phase 1 expansion cohort of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with advanced, refractory sarcomas has been selected for an oral presentation at the upcoming ESMO Congress, to be held October 20 – 24, 2023 in Madrid, Spain.

• Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update

  7/26/2023

  Immuno-oncology leader, Agenus (Nasdaq: AGEN), today announced the Company will release its second quarter 2023 financial results via press release before the market opens on Tuesday, August 8, 2023.

• Agenus Expands Executive Leadership Team

  7/20/2023

  Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team.

• Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO

  6/5/2023

  Agenus, a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, presented complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 at the American Society of Clinical Oncology Annual Meeting.

• Agenus Announces Virtual Annual Shareholders Meeting - June 5, 2023

  6/5/2023

  Agenus today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 12, 2023 and will be conducted in a virtual format only.

• Agenus to Participate in Jefferies 2023 Healthcare Conference

  5/25/2023

  Agenus, an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Jefferies Healthcare Conference on June 8th at the Marriot Marquis in New York.

• Agenus Provides Corporate Update and First Quarter 2023 Financial Results

  5/9/2023

  Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, today provided a corporate update and reported financial results for the first quarter 2023.

• Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI

  5/3/2023

  Agenus announced a data update on botensilimab in combination with balstilimab for patients with non-microsatellite instability-high metastatic colorectal cancer has been selected for a late-breaking oral presentation at the upcoming ESMO World Congress on Gastrointestinal Cancer, to be held June 28 – July 1, 2023 in Barcelona, Spain.

• Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting

  4/26/2023

  Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced plans to present clinical data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, to be held June 2-6 in Chicago, IL.

• Agenus to Provide Corporate Update and First Quarter 2023 Financial Report

  4/25/2023

  Agenus today announced the Company will release its first quarter 2023 financial results before the market opens on Tuesday, May 9, 2023.